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Abstract
Background: Many retinal diseases are associated with vascular dysfunction accompanied by neuroinflammation.
We examined the ability of minocycline (Mino), a tetracycline derivative with anti-inflammatory and neuroprotective
properties, to prevent vascular permeability and inflammation following retinal ischemia-reperfusion (IR) injury, a
model of retinal neurodegeneration with breakdown of the blood-retinal barrier (BRB).
Methods: Male Sprague–Dawley rats were subjected to 45 min of pressure-induced retinal ischemia, with the
contralateral eye serving as control. Rats were treated with Mino prior to and following IR. At 48 h after reperfusion,
retinal gene expression, cellular inflammation, Evan’s blue dye leakage, tight junction protein organization, caspase-3
activation, and DNA fragmentation were measured. Cellular inflammation was quantified by flow-cytometric evaluation
of retinal tissue using the myeloid marker CD11b and leukocyte common antigen CD45 to differentiate and quantify
CD11b+/CD45low microglia, CD11b+/CD45hi myeloid leukocytes and CD11bneg/CD45hi lymphocytes. Major histo-
compatibility complex class II (MHCII) immunoreactivity was used to determine the inflammatory state of these cells.
Results: Mino treatment significantly inhibited IR-induced retinal vascular permeability and disruption of tight junction
organization. Retinal IR injury significantly altered mRNA expression for 21 of 25 inflammation- and gliosis-related genes
examined. Of these, Mino treatment effectively attenuated IR-induced expression of lipocalin 2 (LCN2), serpin peptidase
inhibitor clade A member 3 N (SERPINA3N), TNF receptor superfamily member 12A (TNFRSF12A), monocyte
chemoattractant-1 (MCP-1, CCL2) and intercellular adhesion molecule-1 (ICAM-1). A marked increase in leukostasis of
both myeloid leukocytes and lymphocytes was observed following IR. Mino treatment significantly reduced retinal
leukocyte numbers following IR and was particularly effective in decreasing the appearance of MHCII+ inflammatory
leukocytes. Surprisingly, Mino did not significantly inhibit retinal cell death in this model.
Conclusions: IR induces a retinal neuroinflammation within hours of reperfusion characterized by inflammatory gene
expression, leukocyte adhesion and invasion, and vascular permeability. Despite Mino significantly inhibiting these
responses, it failed to block neurodegeneration.
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Introduction
The intraocular pressure-induced retinal ischemia-
reperfusion (IR) model is a useful tool for studying the
neuronal response to a transient ischemic injury. The
model employs an ischemic period, typically ranging from
45 min up to 120 min, followed by natural reperfusion
that leads to neurodegeneration (for review see [1]).
Electroretinogram (ERG) analysis revealed significant de-
creases in neuronal function one week after IR, with
reduced a-wave and b-wave amplitudes [2]. IR causes loss
of neuronal cells indicated by decreased thicknesses of ret-
inal layers, including the ganglion cell layer (GCL), inner
nuclear layer (INL) and inner plexiform layer (IPL) [3,4].
The apoptotic death of neurons in these layers is indicated
by terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) [5].
Recently it has been recognized that the IR model also
recapitulates changes in the blood-retinal barrier (BRB)
and retinal capillary degeneration observed in diabetic
retinopathy and vein occlusions. Using optical coherence
tomography (OCT), Kim and co-workers [6] recently
demonstrated retinal thickening indicative of edema in
mice 3 d following IR, which was followed by continu-
ous retinal layer thinning for as long as 4 wk after IR. In
addition, IR injury to rats caused a rapid breakdown of
the BRB, with markedly increased retinal vascular per-
meability 4 to 48 h following ischemia [7,8]. Finally, ret-
inal IR injury to rats induced a loss of vascular cells
occurring 7 to 14 days following reperfusion [9-11].
Much less is known about the inflammatory response
to retinal IR injury. Several studies have documented an
induction of pro-inflammatory genes in rodent retinas
following IR, including intracellular adhesion molecule
ICAM-1 and chemoattractants such as CCL2 [11-17].
However, there are few studies examining the conse-
quences of inflammatory gene expression in IR injury.
The accumulation of leukocytes in retinal tissue after IR
has been quantified by nonspecific staining methods
[18-20] and qualitatively observed by immunohisto-
chemistry with antibodies to leukocyte antigens [21,22],
but the characteristics of this leukostasis have not been
examined. Of particular interest is how this inflamma-
tory response relates to neuronal and vascular injury.
Minocycline is a blood–brain barrier (BBB) permeable
tetracycline derivative that exhibits anti-inflammatory, anti-
apoptotic and antioxidant properties, and which inhibits
neuroinflammation and neurodegeneration in the central
nervous system (CNS) (for recent reviews see [23,24]).
Mino inhibits retinal neurodegeneration in several models
of retinopathies, including light-induced injury, axotomy,
experimental glaucoma, photoreceptor degeneration, dia-
betic retinopathy, and IR injury [25-32]. In the present
study we evaluated the abilities of Mino to affect vascular
permeability, inflammation and neurodegeneration in a
rat model of retinal IR employing a relatively short,
45 min, period of elevated intraocular pressure (IOP).
Mino treatment inhibited the induction of a subset of IR-
responsive genes associated with neuroinflammation,
diminished the retinal accumulation of inflammatory mye-
loid leukocytes and lymphocytes, and reduced retinal vas-
cular permeability following IR. In contrast, Mino did not
significantly affect cell death following IR, suggesting that
the anti-inflammatory and anti-permeability effects of
Mino were disassociated from neuroprotection.
Methods
Retinal ischemia-reperfusion and minocycline treatments
Male Sprague–Dawley rats (Charles River Laboratories,
www.criver.com) were maintained under specific pathogen-
free conditions and monitored by quarterly sentinel test-
ing and treated in accordance with the guidelines of the
University of Michigan School of Medicine and Penn State
Hershey College of Medicine Institutional Animal Care
and Use Committees. Ischemia was applied to the left eyes
of rats weighing between 200 g and 225 g by increasing
the intraocular pressure to cut off the retinal arterial blood
supply as previously described [7]. Elevated pressures were
maintained for 45 min before removing needles and allow-
ing natural reperfusion. Sham eyes were treated by briefly
inserting a 32-gauge needle into the anterior chamber of
the eye through the cornea. Unless otherwise stated,
animals were euthanized and retinas removed for ana-
lysis at 48 h following IR. Mino (Sigma-Aldrich Chemical
Co., www.sigmaaldrich.com) was dissolved fresh in
phosphate-buffered saline (PBS) and adjusted to neutral
pH immediately prior to administration. We employed a
Mino treatment regimen used in several previous studies
(see [24]). Mino was delivered as twice-daily intraperito-
neal (IP) injections, with two initial dosages of 45 mg/kg
one day prior to ischemia and dosages of 22.5 mg/kg just
prior to ischemia and every 12 h for the next 2 d during
the reperfusion period. Final injections were given 1 h
prior to harvesting retinas for neurodegeneration or in-
flammation assays, or 1 h prior to injection of Evan’s blue
dye for permeability assays. No treatment controls received
equal volume injections of PBS. For a dose– response
experiment Mino was similarly delivered twice daily, but at
consistent dosages of 22.5, 7.5 or 2.5 mg/kg. (For intravit-
real injection of Mino methods used in Supplemental Data
see Additional file 1: Supplemental Methods).
Retinal permeability assessment
Accumulative blood-retinal barrier leakages were mea-
sured using the Evans blue dye method of Xu and co-
workers [33] as previously described [7]. The dye binds
tightly to serum albumin, thus indicating the leakage of
albumin across the blood-retinal barrier. Statistical dif-
ferences between like-treated Sham and IR retina groups
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were analyzed by paired Student’s t-test, with effects of
treatments analyzed by unpaired Student’s t-test.
Retinal whole mount immunofluorescence
Eyes were removed, punctured and fixed in 4% parafor-
maldehyde in PBS for 15 min at room temperature (RT)
before dissecting retinas. Retinas were removed by orbital
dissection, rinsed in tris-buffered saline containing 0.3%
Triton X100 (TBST) and blocked by incubation in TBST
containing 10% goat serum for 1 h at RT. To examine
leukostasis and leukocyte invasion, retinas were incubated
with mouse anti-rat CD45 (1:50, BD Biosciences, www.
bdbiosciences.com) in TBST plus goat serum for 3 days at
4°C followed by extensive rinsing in TBST for 24 h. Ret-
inas were then incubated with Alexa Fluor-647-labeled
goat anti-mouse IgG (1:1000, Invitrogen-Life Technolo-
gies, lifetechnologies.com), Alexa Flour488-labeled isolectin
B4 (IB4) from Griffonia simplicifolia (1:75, Invitrogen-
Life Technologies, lifetechnologies.com) and 10 μg/ml
Hoechst-33342 DNA stain (Invitrogen-Life Technologies,
lifetechnologies.com) in TBST for 24 h at RT followed
by extensive rinsing in TBST for 24 h. To examine
endothelial tight junction organization, retinas were in-
cubated with rabbit anti-Zonula occludens 1 (ZO-1)
antibody (1:50, Invitrogen-Life Technologies, lifetechnol-
ogies.com) and then with Alexa Fluor 594-conjugated
anti-rabbit IgG secondary antibody (1:1000, Invitrogen-
Life Technologies, lifetechnologies.com). Retinas were
flat mounted on 3-aminopropyltriethoxysaline-coated
slides with Prolong Gold mounting media (Invitrogen-
Life Technologies, lifetechnologies.com). Images were ac-
quired with a Leica TCS SP5 AOBS confocal microscope
(www.leica-microsystems.com).
Vascular endothelial cell border organization grading
Confocal Z-stacks of 10 images collected over a depth of
5 μm were projected as one composite image. Loss of
vascular ZO-1 organization at endothelial cell borders was
quantified by a semi-quantitative rank scoring system
based on a scale of 1 to 5, with 1 corresponding to
complete loss of continuous border staining and 5 corre-
sponding to entirely continuous border staining. Scoring
was completed in a masked fashion by three impartial ob-
servers who were provided scored images for reference.
For each group or retinas, the scores for 8 to 18 images
from three independent experiments were obtained and
the frequencies for each ranking score calculated and plot-
ted. Statistical differences between mean values of rank
scores for each group were analyzed by one-way ANOVA.
Examination of retinal gene expression by quantitative
real-time polymerase chain reactions
Retinas were removed, flash-frozen in liquid nitrogen, and
stored at −80°C until analysis. Total RNA was purified
from retinal tissues using RNeasy Plus™ Mini kit (Qiagen,
www.qiagen.com) with and QiaShredders™ (Qiagen, www.
qiagen.com). Quantitative real-time polymerase chain re-
action (qRT-PCR) was performed by reverse transcription
of 0.8-1.0 μg of total RNA using random hexamers and
oligo-dT primers in the presence of RNase inhibitor
(Omniscript™ RT kit, Qiagen, www.qiagen.com). Duplex
qPCRs were performed using the equivalent of 1 μl of RT
reaction with gene-specific primers and FAM-labeled
probes (Applied Biosystems Life Technologies, lifetechnol-
ogies.com), along with β-actin-specific primers and VIC-
labeled probes (primer limited formulation, Applied
Biosystems Life Technologies, lifetechnologies.com) and
TaqMan™ Universal PCR master mix (Applied Biosystems
Life Technologies, lifetechnologies.com). Primer-probe
assay information and measured efficiencies obtained in
duplex reactions are provided in (Additional file 2: Table S1).
Reactions were performed and monitored using a CFX384
real time PCR system (BioRad, www.bio-rad.com). Relative
normalized mRNA levels were calculated using the ΔΔCt
method. Statistical differences between like-treated Sham
and IR retina groups were analyzed by paired Student’s
t-test, with effects of treatments analyzed by unpaired
Student’s t-test.
Analysis of leukostasis and leukocyte infiltration by
flow cytometry
Retinas were removed by orbital dissection and IR and
sham retinas pooled (2 to 4 retinas per group). Tissues
were diced with a scalpel into <1 mm pieces and then
centrifuged at 400 ×g for 5 minutes at RT. Pelleted tissues
were resuspended in a total of 500 μL of Hepes-buffered
saline (HBSS) with 0.5 mg/ml of Liberase enzyme mix
(TM research grade, Roche Applied Science, www.roche-
applied-science.com) and 0.1 mg/ml DNase (Bovine
Grade II, Roche Applied Science, www.roche-applied-
science.com) and incubated at 37°C for 25 to 30 min with
occasional agitation. After incubation, 10 ml of Dulbecco’s
modified Eagles media (DMEM) containing 10% fetal bo-
vine serum (FBS) was added to the reaction and retinal
cells were forcibly strained three times through a 40-μM
nylon mesh strainer using the rubber end of a syringe
plunger. The strained cell suspension was centrifuged at
400 ×g for 5 min at RT and the pellet resuspended in 5 ml
of HBSS. To remove clumps of cells, the suspension was
centrifuged at 50 ×g for 1 min at RT, and the pellet dis-
carded. The supernatant was centrifuged at 400 ×g for
5 min at RT and the cellular pellet resuspended in 500 μl
of HBSS and transferred to several wells of a U-bottomed
96-well plate for antibody staining. Cells were centrifuged,
pellets resuspended in 50 μl of PBS containing 20% rat
serum and 1 μg/ml Fc-blocking antibody (mouse anti-rat
FcγII/CD32, clone D34-485, BD Biosciences, www.bdbio-
sciences.com) and incubated for 20 min on ice. Biotin-
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conjugated anti-rat RT1B/MHCII antibody (1:10 volume,
clone OX-6, Serotec, www.abdserotec.com) was added
and the incubation was continued for 45 min on ice. After
rinsing three times in PBS, cells were resuspended in PBS
containing 20% rat serum with RPE-conjugated anti-rat
CD11b monoclonal antibody (1:50 volume, clone OX-42,
AbD Serotec, www.abdserotec.com), FITC-conjugated
anti-rat CD45 monoclonal antibody (1:50 volume, clone
OX-1, AbD Serotec, www.abdserotec.com), and APC-
Cy7-conjugated streptavidin (1:100 volume, BD Biosci-
ences, www.bdbiosciences.com) and incubated for 45 min
on ice. After being rinsed, cells were analyzed using an
LSRII flow cytometer (BD Biosciences, www.bdbiosciences.
com). CompBeads (BD Biosciences, www.bdbiosciences.
com) anti-mouse Ig particle compensation set was incu-
bated with each antibody or biotin-avidin-antibody pair
for compensation corrections for spectral overlaps. Cyt-
ometer data was analyzed using FlowJo software (Tree
Star Inc., www.treestar.com). To avoid events representing
debris and clumps of cells, events were gated from scatter
plots of forward and side scatter in identical fashions for
each group prior to analysis of CD11b, CD45 and MHCII
immunostaining intensities. Statistical differences between
like-treated Sham and IR retina groups were analyzed by
paired Student’s t-test, with effects of treatments analyzed
by unpaired Student’s t-test.
Evaluation of retinal cell death
Caspase-3 (DEVDase) activity was measured in retinal
homogenates using the fluorometric CaspACE assay
system (Promega, www.promega.com) as previously de-
scribed [7]. Apoptotic DNA cleavage was assayed using
a Cell Death Detection ELISA Kit (Roche Applied Sci-
ence, www.roche-applied-science.com) and normalized
to retinal wet weight as previously described [7]. Statis-
tical differences between like-treated Sham and IR retina
groups were analyzed by paired Student’s t-test, with ef-
fects of treatments analyzed by unpaired Student’s t-test.
(For additional retinal cell methods used in Supplemental
Data see Additional file 1: Supplemental Methods).
Results
Minocycline treatment inhibited retinal vascular
permeability following ischemia-reperfusion
Using a rat model of IR injury caused by 45 min of is-
chemia, we previously demonstrated that both retinal
neurodegeneration and increased vascular permeability
occurs at 4 h to 48 h following IR [7]. We hypothesized
that Mino could protect against vascular dysfunction in
this model, and, thus, effects of Mino treatment on the
retinal vascular leakage after 48 h of reperfusion were
tested. We chose to use a treatment regimen employing
twice-daily IP injections of Mino with two initial loading
doses of 45 mg/kg followed by doses of 22.5 mg/kg,
which has been used in several previous rat studies of
ischemic injury and neurodegeneration (listed in [24]).
Mino treatment significantly (P <0.05) inhibited the in-
crease in retinal Evans blue dye accumulation, a measure
of vascular albumin leakage, at 48 h after IR by 61%
(Figure 1A). In addition, we found that intravitreal injec-
tion of Mino (640 ng/eye injected 1 h before and 4 h
after IR) also significantly (P <0.05) inhibited the vascu-
lar permeability increase 24 h following IR to a very
similar extent (77%) as observed with systemic Mino
treatment (see Additional file 3: Figure S1A). These data
suggest that Mino acts locally to reduce retinal perme-
ability at 24 to 48 h after IR. However, when the effect
of Mino treatment on vascular permeability was exam-
ined immediately following IR, the drug had no signifi-
cant effect (see Additional file 4: Figure S2).
ZO-1 represents a central organizing protein in the
junction complex comprising the BRB [34]. To assess
organization of the endothelial tight junction complex,
localization of ZO-1 was imaged in retinal flat mounts by
immunofluorescence (IF) and confocal microscopy. At
48 h following IR ZO-1 localization was apparently altered
specifically at arterioles in this IR model (Figure 1B). Fur-
ther, Mino treatment significantly reversed the perturb-
ation of ZO-1 localization, as indicated by masked image
scoring performed by impartial evaluators (Figure 1C).
Minocycline treatment inhibited expression of
ischemia-reperfusion-responsive genes associated with
neuroinflammation, but not those associated with
astrogliosis following ischemia-reperfusion
To examine the effect of Mino treatment on the inflam-
matory response following IR we used qRT-PCR analysis
to examine the expression levels of 25 mRNAs at 48 h
following IR in rats systemically treated with or without
Mino as described above. The mRNAs examined were
chosen from a previously obtained transcriptomics data
set for this rat IR model [7], with preference for genes
associated with inflammation and astrogliosis (see
Additional file 2: Table S1). For comparison, the induc-
tion of expression of each of these mRNAs in retinas 4 h
following intravitreal injection of 1 μg/eye of lipopoly-
saccharide (LPS) was also examined. Retinal expression
of 21 of these mRNAs were significantly altered by IR,
with 20 mRNAs increased from 89% (CHI3L1) to 47.6
fold (CCL2) and only glutamate ammonia ligase (GLUL)
significantly decreased 55% by IR (see Additional file 2:
Table S1). Significantly increased mRNA expression was
observed for several pro-inflammatory genes, including:
C-X-C motif chemokine ligand 2 (CXCL2, 5.3-fold,
P <0.001), interleukin-6 (IL6, 9.5-fold, P <0.001,
interleukin-1beta (IL1B, 7.5-fold, P = 0.03), tumor necrosis
factor alpha (TNF, 9.1-fold, P <0.001), C-X-C motif che-
mokine ligand 1 (CXCL1, 5.5-fold, P <0.001), C-C motif
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chemokine ligand 3 (CCL3, 9.6-fold, P <0.001) and CD14
molecule (22.2-fold, P <0.001). In contrast, expression of
three mRNAs that are characteristic of classical inflamma-
tion, C-X-C motif chemokine ligand 10 (CXCL10),
inducible nitric oxide synthase 2 (NOS2, iNOS) and
prostaglandin-endoperoxide synthase 2/cyclooxygenase 2
(PTGS2, COX2), were not significantly altered at 48 h
after IR. However, the retinal levels of these three mRNAs
were significantly increased by LPS injection by 4700-fold
(P = 0.05), 63-fold (P <0.001) and 9.4-fold (P <0.001),
respectively. Expression of mRNAs representing two
markers of astrogliosis, glial fibrillary acidic protein
(GFAP) and vimentin (VIM), were significantly (P <0.001)
increased by 6.8-fold and 3.0-fold, respectively, by IR.
Neither of these mRNAs was responsive to LPS injection.
Comparing mRNA levels in sham-treated eyes from
rats treated with and without Mino revealed that drug
treatment alone significantly affected the expression of
Figure 1 Minocycline (Mino) treatment significantly inhibited retinal vascular leakage and tight junction reorganization following
ischemia-reperfusion (IR). Mino was delivered as twice-daily intraperitoneal (IP) injections, with two initial dosages of 45 mg/kg prior to ischemia
and dosages of 22.5 mg/kg just prior to ischemia and every 12 h for the next 2 d during the reperfusion period as described in Materials and
Methods. Non-treated (NT) animals received PBS vehicle injections. One eye of each rat was subjected to IR for 45 min or needle puncture only
(Sham) and after 48 h of reperfusion retinas were assayed for (A) Evans blue dye leakage (n = 8 retinas per group), or (B and C) for vascular
endothelium tight junction organization by immunohistochemistry of ZO-1 protein at endothelial cell borders (n = 4 retinas per group). Representative
images from Sham and IR retinas are shown in B, with arrowheads indicating intact borders and arrows indicating regions of ZO-1 discontinuity.
Distributions of endothelial cell border organization grading frequency are shown in C, with five representing fully continuous border staining and one
representing complete loss of continuous border staining. *P ≤0.05, **P ≤0.01 and *** P ≤0.001 by Student’s t-test.
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five mRNAs, including IL6 (increased 2.5-fold, P = 0.01),
C-C motif chemokine ligand 5 (CCL5, decreased 35%,
P = 0.05), endothelin 2 (EDN2, decreased 49%, P = 0.05),
CCL3 (decreased 30%, P = 0.03) and the lectin galectin
binding soluble 3 (LGALS3, decreased 70%, P = 0.002)
see (Additional file 2: Table S1). Mino also significantly
inhibited the IR-induced expression of 5 genes (Figure 2).
These included ICAM-1 (51% inhibition, P <0.001),
lipocalin 2 (LCN2, 59% inhibition, P = 0.008), serpin
peptidase inhibitor clade A member 3 N (SERPINA3N,
91% inhibition, P = 0.02), TNF receptor superfamily
member 12A (TNFRSF12A, 27% inhibition, p = 0.03)
and CCL2 (63% inhibition, P = 0.04). The inhibitory ef-
fects of Mino treatment on the IR responses of several
other pro-inflammatory genes were nearly significant.
These included: CXCL2 (54% inhibition, P = 0.06), IL6
(63% inhibition, P = 0.06), IL1B (82% inhibition, P =
0.07), and TNF (30% inhibition, P = 0.07) (see Additional
file 2: Table S1). In contrast, Mino treatment did not
significantly affect the IR responses of GFAP (Figure 2F)
Figure 2 Minocycline (Mino) treatment significantly diminished neuroinflammatory gene expression following ischemia-reperfusion
(IR) without affecting astrogliosis-related gene expression. Mino was delivered as twice-daily intraperitoneal (IP) injections, with two initial
dosages of 45 mg/kg prior to ischemia and dosages of 22.5 mg/kg just prior to ischemia and every 12 h for the next 2 d during the reperfusion
period as described in Materials and Methods. Non-treated (NT) animals received PBS vehicle injections. One eye of each rat was subjected to IR
for 45 min or needle puncture only (Sham) and after 48 h of reperfusion total RNA was isolated from retinas and relative mRNA levels of
neuroinflammation-related genes (A) ICAM-1, (B) LCN2, (C) TNFRSR12A, (D) SERPINA3N, (E) CCL2 and (F) the astrogliosis-related gene GFAP by
duplex qRT-PCR with β-actin mRNA serving as control. Results shown are the means and standard error of means obtained from eight animals
per group. *P ≤0.05, **P ≤0.01 and ***P ≤0.001 by Students t-test.
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and VIM (see Additional file 2: Table S1), with calcu-
lated inhibitions of 10% and 2%, respectively. Thus,
Mino had a generally inhibitory effect on the expression
of pro-inflammatory genes following IR without altering
the astrogliosis response to retinal IR injury.
Minocycline treatment inhibited cellular inflammation
following ischemia-reperfusion
Given that Mino reduced the overall transcriptional pro-
inflammatory response to IR and significantly inhibited
the induction of expression of the monocyte chemo-
attractant CCL2 as well as the leukocyte adhesion mol-
ecule ICAM-1, we hypothesized that Mino treatment
inhibits the attraction, vascular adherence and invasion of
monocytes to retinal tissue following IR, thus leading to a
diminished cellular inflammation. Figure 3 shows repre-
sentative images of retinal flat mounted Sham and IR
retinas harvested 48 h after IR and probed with antibody
to CD45 to detect leukocytes and with IB4 lectin, which
binds with high affinity to endothelial cells [35] and also
labels infiltrating neutrophils [36]. The appearance of
CD45-positive leukocytes was apparent in IR retinas, with
the vast majority of these cells found within the vascular
lumen and most abundant within intermediate-sized arte-
rioles and venules. These cells were essentially absent in
Sham retinas. A few amoeboid cells exhibiting uniform
peripheral CD45 staining were also identified within IR
injured retinas; these were not found in retinas from Sham
treated eyes. Although microglia express low levels of
CD45, no cells with ramified morphology resembling
microglia were observed to exhibit CD45 staining above
background levels in either Sham or IR retinas. Thus, this
qualitative analysis demonstrated an obvious leukostasis
with occasional tissue invasion of leukocytes 48 h after IR.
Next we used flow cytometry to quantify and better
characterize this leukostasis response, as well as to test
the effects of Mino treatment on this cellular inflamma-
tion at 48 h following IR (Figure 4). By probing all retinal
cells for surface expression of CD45 and the myeloid
marker CD11b the CD11b+/CD45low cells (evidently
microglia), CD11b+/CD45hi cells (myeloid leukocytes) and
CD11bneg/CD45hi cells (non-myeloid leukocytes, aka lym-
phocytes) were gated and each population quantified rela-
tive to the total number of retinal cells (Figure 4A). To
Figure 3 Leukostasis and retinal tissue invasion of CD45-positive leukocytes following ischemia-reperfusion (IR). Eyes were subjected to
IR for 45 min or needle puncture only (Sham) and after 48 h of reperfusion retinas were removed, stained with antibodies to CD45 (magenta),
isolectin B4 (IB4, green) and Hoechst nuclear stain (blue) and then flat mounted. Representative images showing CD45-staining leukocytes within
IB4-stained vessels from IR retina (A) and sham retina (B) are shown along with magnified images (C and D) of CD45-positive cells (arrows) found
within retinal tissue from IR retinas.
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obtain information regarding the inflammatory state of
the cells, the populations were also gated by surface ex-
pression of MHCII with MHCIIneg and MHCII+ subpopu-
lations quantified (Figure 4B). Figure 4C indicates that IR
caused a slight (30%) but significant (P <0.05) increase in
the average total fraction of CD11b+/CD45low cells
(MHCIIneg plus MHCII+). CD11b+/CD45low cells exhib-
ited a unimodal distribution of MHCII content with ap-
proximately 2/3 of cells exhibiting an MHCII-negative
phenotype and 1/3 with MHCII antibody staining inten-
sity only slightly above that of the no antibody control.
This distribution was not obviously altered by IR and the
mean fluorescence intensity of MHCII antibody staining
was not significantly altered (data not shown). However,
the slight increase in CD11b+/CD45low cell numbers fol-
lowing IR was primarily due to an increase of cells exhibit-
ing low MHCII immunoreactivity. Mino treatment had no
significant effects on the retinal microglial numbers in
sham treated or IR injured retinas.
Consistent with the IF results, the relative numbers of
all CD45-positive leukocytes were markedly increased by
IR. This was due to significant increases (P <0.001) of
Figure 4 Minocycline (Mino) treatment significantly diminishes cellular inflammation following ischemia-reperfusion (IR). Mino was
delivered as twice-daily intraperitoneal (IP) injections, with two initial dosages of 45 mg/kg prior to ischemia and dosages of 22.5 mg/kg just prior
to ischemia and every 12 h for the next 2 d during the reperfusion period. Non-treated (NT) animals received PBS vehicle injections. One eye of
each rat was subjected to IR for 45 min or needle puncture only (Sham) and after 48 h of reperfusion retinas were enzymatically dissociated and
cells analyzed by flow cytometry. (A) Representative scatter plots of CD11b and CD45 immunostaining intensities of total retinal cells from Sham
and IR retinas of rats treated with PBS or Mino. Events are partitioned into quadrant 1 (Q1) containing CD11b+/CD45low cells, quadrant 2 (Q2)
containing CD11b+/CD45hi cells and quadrant 3 (Q3) containing CD11bneg/CD45hi cells. The fourth quadrant contains the majority of retinal cells,
which are CD11bneg/CD45neg. (B) Example of MHCII staining distributions of cells from quadrants 1, 2 and 3. Red traces are for cells from
Sham-treated retinas, blue traces are for cells from IR retinas and the black trace is for cells incubated without the MHCII antibody and used to
define the intensity cutoff between define MHCII+ and MHCIIneg cells. (C) Quantification of total events, MHCII+ events and MHCIIneg events from
quadrants 1, 2 and 3 from Sham and IR retinas from PBS- and Mino-treated rats. The numbers shown are mean percentiles relative to all events,
including those in quadrant 4, obtained from three separate flow experiments, with a total of 11 to 12 determinations per group. Significant
differences between Sham and IR groups are indicated as *P ≤0.05, **P ≤0.01 and ***P ≤0.001, while significant effects of Mino-treatment are
indicated by #P ≤0.05 and ##P ≤0.01. All comparisons are by Students t-test.
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both CD11b+/CD45hi myeloid cells (increased more than
5-fold from 0.016 to 0.086% of all events) and CD11bneg/
CD45hi lymphocytes (increased nearly 5-fold from 0.037%
to 0.18%) following IR (Figure 4C). Thus, the CD45-
positive leukocytes accumulating in the retina following
IR were composed of approximately 1/3 myeloid cells and
2/3 lymphocytes. CD11b+/CD45hi myeloid cells exhibited
a clear bimodal distribution of MHCII-content, which was
particularly evident following IR due to a large increase in
cells with a relatively high MHCII expression. IR signifi-
cantly (P <0.001) increased MHCII+ myeloid leukocytes
by more than 8-fold (from 0.008 to 0.066%). IR also sig-
nificantly (P <0.01) increased the number of MHCIIneg
myeloid leukocytes, but only by 3-fold (from 0.007 to
0.020%). In contrast to myeloid cells, CD11bneg/CD45hi
lymphocytes in the retina exhibited a broad unimodal
MHCII distribution. Although separation of this popula-
tion by MHCII expression was thus less practical, gating
into MHCII+ and MHCIIneg populations was done for
sake of comparison. IR significantly (P <0.001) increased
accumulation of nominally MHCII+ myeloid leukocytes
by 5-fold (from 0.028 to 0.14%), and significantly (P <0.01)
increased MHCIIneg myeloid leukocytes by more than 4-
fold (from 0.009 to 0.040%). Thus, the majority of myeloid
and non-myeloid leukocytes accumulating in the retina
after IR were MHCII-positive. Collectively, this data re-
vealed that both myeloid and lymphocytic cells are signifi-
cantly increased in the retina 48 h after IR with a
predominant increase in MHCII+ cells, while IR had a
limited effect on the number of resident microglia.
Mino treatment significantly inhibited the increase in
both myeloid leukocytes and lymphocytes following IR
(Figure 4). In Mino-treated rats the increase in CD11b+/
CD45hi myeloid cell numbers following IR was signifi-
cant (P <0.05) but much lower than that observed in
non-treated rats (2-fold versus 5-fold), corresponding to
a 72% inhibition by Mino (P <0.05). The increase of
CD11bneg/CD45hi lymphocytes was also significant
(P <0.01) in Mino-treated rats, but similarly reduced by
71% by Mino (2-fold versus nearly 5-fold). Gating of pop-
ulations by MHCII expression revealed that the inhibitory
effect of Mino treatment was biased toward MHCII+ leu-
kocytes. Mino significantly (P <0.01) inhibited the increase
of CD11b+/CD45hi/MHCII+ myeloid leukocytes by nearly
80% following IR. In contrast, Mino nominally inhibited
the accumulation of MHCIIneg myeloid leukocyte popula-
tion following IR by only 45% (P = 0.25). With Mino treat-
ment the accumulation of CD11bneg/CD45hi/MHCII+
lymphocytes in response to IR was significantly reduced
by 72% (P <0.05) compared to non-treated rats. For
MHCIIneg lymphocytes, the calculated inhibition by Mino
was similarly 70%, however, the effect of Mino did not
reach significance (P = 0.08). In sum, Mino dramatically
reduced the increase in myeloid cells and lymphocytes
following IR with the prevalent effects being on MHCII+
populations.
Minocycline did not significantly inhibit
neurodegeneration following ischemia-reperfusion
To test the effect of Mino treatment on retinal cell death
at 48 h following IR the previously established [7] end-
points of caspase-3 activation and DNA fragmentation
were employed. Mino failed to significantly affect these
indicators of neurodegeneration (Figure 5A and B). Be-
cause of evidence that 5 to 10 times lower doses of Mino
can provide greater neuroprotection (reviewed in [24]) we
performed a dose–response experiment employing a dose
essentially the same as prior experiments but lacking the
increased loading dosage, as well as doses 3 times and 9
times lower than before. None of these doses of Mino sig-
nificantly inhibited apoptosis (Figure 5C). Furthermore,
while local intravitreal injection of Mino significantly
(P <0.05) prevented IR-induced vascular permeability to
a similar extent as systemic delivery of the drug, this treat-
ment had no significant effect on DNA fragmentation or
accumulative measures of neurodegeneration, including
retinal layer thinning or the reduction of the ERG b-wave
amplitudes measured at 2 wk and 1 wk following IR, re-
spectively (see Additional file 3: Figure S1). Thus, Mino
treatments that significantly reduced vascular permeability
and inflammatory responses had no significant effect on
neurodegeneration in this model.
Discussion
Mino reduced IR-induced neuroinflammation, including
the expression of inflammatory genes and leukostasis,
and prevented IR-induced permeability and tight junc-
tion disorganization. To the best of our knowledge the
present study is the first to examine the effects of Mino
on vascular permeability and cellular inflammation fol-
lowing retinal IR. In fact, there are very few published
studies of any kind on Mino’s effects on retinal vascular
permeability. Chen and coworkers [37] demonstrated
that Mino treatment diminished Evans blue dye leakage
following repeated intravenous injection of glycated al-
bumin into rats [37]. Using OCT, Sun et al. observed
that Mino treatment significantly inhibited edema in the
inner retina at 3 d following branch retinal vein occlu-
sion (BRVO) [38]. On the other hand, several studies
have demonstrated that Mino reduced brain edema in
models of cerebral IR [39-41], stroke [42-44], as well as
traumatic brain injury, infection and neurodegeneration
[45-48]. Intriguingly, a small clinical study of five pa-
tients with diabetic macular edema found that 6 mo of
Mino treatment reduced vascular fluorescein leakage
and diminished mean retinal thicknesses [49].
The lack of neuroprotection by Mino observed in the
present study is surprising because Mino is well known
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as a neuroprotective agent (reviewed in [50]). Mino was
not significantly neuroprotective according to measures at
48 h following IR (caspase-3 activity and DNA fragmenta-
tion, Figure 5), at 24 h following IR (DNA fragmentation,
(see Additional file 3: Figure S1B)) and by accumulative
measures at 1 to 2 wk following IR (ERG and retinal layer
thinning, (see Additional file 3: Figures S1C and D)). Pre-
viously, Mino inhibited retinal neurodegeneration in
models of diabetic retinopathy [25], light induced retinop-
athy [26,27], glaucoma [28,29], axotomy [28,30] and ret-
inal detachment [31]. Mino also inhibited the death of
retinal neurons induced by glutamate and trophic factor
withdrawal [51]. More applicable to the ischemic retina,
Mino had small but significant effects on RGC loss and
IPL thinning, while failing to prevent loss of ERG b-wave
responses, in a rat model of BRVO [38]. In direct contrast
to the present results, Mathalone and colleagues observed
that systemic Mino treatment protected against RGC loss
and inner retinal layer thinning following IR in the rat
[52]. The reasons for this discrepancy are unknown.
Matholone et al. employed relatively low Mino doses of
2.5 and 5 mg/kg-day and a 90 min ischemic insult that
resulted in almost total disappearance of the IPL, rather
than the 21% reduction in IPL thickness observed herein
(see Additional file 3: Figure S1). While lower doses of
Mino may actually be more neuroprotective than 45 mg/
kg-day [24], in the present study Mino doses of 15 mg/
kg-day and 5 mg/kg-day also failed to significantly inhibit
DNA fragmentation following IR (Figure 1D). Thus, the
dosing regimen is unlikely the reason for lack of neuro-
protection. Regardless of the reason for the observed lack
of neuroprotection, the present results demonstrate that
inflammatory and vascular response can be disassociated
from the neurodegenerative response to IR.
It is possible that Mino’s ability to inhibit inflamma-
tion and inflammatory cell attraction may reduce leakage
at 24 to 48 h after IR by averting endothelial damage
caused by adherent or invading leukocytes. However,
the data does not provide direct evidence of a linkage
between leukostasis and vascular dysfunction. Such evi-
dence was presented by Hirata and co-workers [22] who
used silver nitrate staining of endothelial cell boundaries
and an antibody to CD45 to show that a Rho-associated
kinase inhibitor, Y-27632, blocked leukostasis that was
spatially associated with gaps in the endothelial layer
following rat retinal IR. In contrast to Mino treatment,
Y-27632 also inhibited ganglion cell loss and IPL thin-
ning following IR. Although we did not observe apparent
gaps in the vascular endothelium following IR, it is
possible that damage to the endothelium contributes to
leakiness following retinal IR. Danesh-Meyer and col-
leagues observed evidence of endothelial cell loss follow-
ing retinal IR [8]. These authors found that inhibition of
connexin43 gap junction activity prevented both neuronal
Figure 5 Minocycline (Mino) treatment did not prevent cell death
following ischemia-reperfusion (IR). (A and B)Mino was delivered as
twice-daily intraperitoneal (IP) injections, with two initial dosages of
45 mg/kg prior to ischemia and dosages of 22.5 mg/kg just prior to
ischemia and every 12 h for the next 2 d during the reperfusion period as
described in Materials and Methods. One eye of each rat was subjected to
IR for 45 min or needle puncture only (Sham) and after 48 h of reperfusion
retinas were assayed for (A) caspase-3 activity and (B) DNA fragmentation
cell death ELISA. (C) Mino dose–response. Rats were IP injected twice daily
with PBS, 2.5 mg/kg (Mino-5), 7.5 mg/kg (Mino-15) or 22.5 mg/kg
(Mino-45) beginning 24 h previous to ischemia, and 48 h following IR
retinas were assayed by DNA fragmentation cell death ELISA. Results
shown are the means and standard error of means obtained from eight
animals per group. *P ≤0.05, **P ≤0.01 and ***P ≤0.001 by Student’s t-test.
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cell death and vascular leakage. Similarly, Krueger and
co-workers recently found that leakiness of the BBB in a
stroke model was primarily located in regions with in-
tact tight junctions and with evidence of increased
transcellular vesicle trafficking and endothelial cell dis-
integration [53]. The failure of Mino to prevent leakage
immediately after IR (see Additional file 4: Figure S2)
suggests that early and late permeability are caused by
different mechanisms. We recently found that vascular
leakiness immediately following IR coincided with phos-
phorylation and ubiquination of the tight junction pro-
tein occludin (A. Muthusamy et al., in press). Thus, it is
possible that Mino treatment inhibits vascular perme-
ability by protecting tight junction alterations (as ob-
served in this study), and also by inhibiting transcellular
trafficking and preventing endothelial cell death (not
directly investigated in this study). Future studies using
biochemical and genetic approaches specifically target-
ing the vascular endothelium or infiltrating leukocytes
may allow further testing of a causal relationship be-
tween inflammation and endothelial cell destruction
and/or disruption of the BRB. Prevention or inhibition
of inflammation may reduce permeability by inhibiting
all of these potential routes of flux.
IR induced neuroinflammation that was inhibited by
Mino treatment. We developed a set of 25 mRNA
markers to monitor the inflammatory and astrogliosis
responses of the retina to IR injury. The responses at
48 h following IR were very different from those ob-
served after intravitreal injection of LPS, which repre-
sents a classical inflammatory insult mediated by
activation of toll like receptor 4 (TLR4). The expressions
of mRNAs corresponding to genes associated with clas-
sical inflammation (ICAM-1, CCL2, IL6, IL1B, TNF and
CXCL2) were significantly increased in IR. However, the
induction of these mRNAs by IR was dwarfed by the in-
duction observed following intravitreal LPS injection.
Several studies have documented induction of classical
pro-inflammatory genes, including NOS2, COX2, TNF-
α, IL-1β, and IL-6, in rodent retinas within hours of IR
[11-17]. The lack of induction of NOS2, COX2, CCL5,
and CXCL10 mRNAs 48 h following IR, as well as the
relatively small induction of TNF-α, IL-1β, IL-6 and
CXCL2 suggests a fundamental difference from classical
inflammation. Several mRNAs indicative of neuroinflam-
mation were significantly upregulated, including SERPI-
NA3N, TNFRSF12A, endothelin 2 (EDN2), sphingokinase
1 (SPHK1), CHI3L1 and LGALS3. Intravitreal injection of
LPS caused either much less induction or no induction of
these neuroinflammatory markers. Thus, the response to
IR may be more characteristic of the non-classical neuro-
inflammation that has been termed ‘pseudo-inflammation’
and has been largely attributed to the response of the in-
nate immune system composed of glial and microglial
cells [54]. The significant induction of GFAP and VIM
mRNAs, as well as the significant reduction of GLUL
mRNA, suggests that Müller cells, and possibly astrocytes
undergo astrogliosis following IR.
Mino significantly inhibited the increase in expression
of CCL2 and ICAM1 mRNAs. It is likely that the inhib-
ition of expression of CCL2 and ICAM1 contributed to
the inhibition of leukostasis by reducing the attraction
and adhesion of leukocytes to the retinal vascular endo-
thelium. Retinal IR injury upregulates both P-selectin
and ICAM1 expression, presumably leading to increased
leukocyte rolling and adhesion on the endothelial lumen
[55]. Blocking antibodies to P-selectin or ICAM-1 also
inhibited leukostasis and retinal layer thinning following
IR [56]. We did not include P-selectin in our set of IR-
responsive mRNA markers, as the original transcrip-
tomic analysis did not identify it as being significantly
altered by IR [7].
Flow cytometric quantification of CD11b and CD45
leukocyte markers was used to quantify the accumula-
tion of immune cells in the retina following IR. Resident
microglia constitute the vast majority of the CD11b+/
CD45low population in retina and the central nervous
system [57-61]. We observed a slight but significant 30%
increase in the number of CD11b+/CD45low cells follow-
ing IR, which was not affected by Mino treatment. We
do not know if this apparent increase represents prolifer-
ation of the resident microglial population or an influx
of circulating monocytes. There was a very significant
increase in the number of CD11b+/CD45hi cells follow-
ing IR. CD11b positivity with high levels of CD45 is a
classic indicator of myeloid leukocytes, which include
mature macrophages, monocytes, granulocytes (primar-
ily neutrophils) and dendritic cells. It is probable that
retinal resident dendritic cells are included in this popu-
lation. Indeed, in the basal state mouse retina contains
approximately 100 dendritic cells per retina [62]. Using
flow cytometry, we observed a highly significant accu-
mulation of both CD11b+/CD45hi myeloid leukocytes
and CD11bneg/CD45hi non-myeloid lymphocytes after
IR. The accumulations of these populations were signifi-
cantly attenuated by Mino treatment.
Expression of MHCII is a characteristic of antigen pre-
senting cells (APC), including monocytes, macrophages,
dendritic cells and B-lymphocytes. MHCII can also be
expressed by activated T-cells [63]. Subdividing inflam-
matory cells into MHCII-positive and MHCII-negative
groups revealed that Mino more significantly inhibited
the accumulation of the MHCII+ subpopulations, suggest-
ing that it acts to preferentially block the accumulation
of inflammatory leukocytes. The seemingly preferential
action of Mino may also be due to a shift in MHCII ex-
pression. Mino inhibited the upregulation of MHCII ex-
pression in microglia and macrophages during activation
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by gamma-interferon [64]. Thus, it is possible that Mino
inhibited the accumulation of both MHCII positive and
negative leukocytes equally, but also shifted MHCII+
populations toward a less activated state.
The molecular mechanism by which Mino may act to
reduce inflammation and vascular permeability following
IR is uncertain. In addition to its bacteriostatic capabil-
ities, Mino is endowed with several functional properties
that lead to pleiotropic effects [23]. Mino inhibits
caspase-1 mRNA expression in cerebral IR [65] and a
Huntington disease model [66]. Caspase-1 is also known
as interleukin-1β converting enzyme (ICE), an integral
part of the inflammasome. Mino inhibited caspase-1 ac-
tivity and IL-1β expression in retinas of diabetic mice
[67]. Mathalone and colleagues argued that Mino’s abil-
ity to inhibit metalloproteinase activities was responsible
for the neuroprotective effects of Mino following IR in
the rat [52]. Metalloproteinases have also been impli-
cated in disruption of the BBB and permeability in cere-
bral ischemia (for review see [68]). Due to its phenolic
rings and dimethylamino group on a phenolic carbon,
Mino also acts as an effective scavenger of reactive oxy-
gen species (ROS) [69]. Given that ROS are implicated
in the mechanism of vascular dysfunction following IR
[70], the ability of Mino to scavenge ROS could also
conceivably account for its vascular protective abilities
following IR.
Conclusions
Retinal diseases invariably involve a combination of neu-
rodegeneration, vascular dysfunction and inflammation
in various proportions. The retinal IR injury model has
primarily been used to explore means to prevent the
neurodegenerative response triggered by a transient is-
chemic insult, but it also provides a useful means to
explore the prevention of vascular and inflammatory
responses to injury. Although Mino can undoubtedly be
neuroprotective, the present study found that Mino
diminished retinal neuroinflammation, leukostasis and
vascular leakage without affecting indicators of astroglio-
sis or neuronal cell death. The molecular mechanisms
by which Mino mediated the inflammatory and vascular
responses to IR were not identified, but we can reason-
ably conclude that this was not the result of reducing
the extent of neuronal damage caused by IR. The ability
of Mino to inhibit the expression of chemokines such as
CCL2 and adhesion molecules such as ICAM-1 would
be expected to diminish leukostasis. Further studies are
needed to determine the extent to which inflammatory
gene expression and/or leukostasis following IR causes
vascular dysfunction and leakage, perhaps by damaging
the endothelium. Our data suggest that there is also a dir-
ect effect of IR on endothelial tight junction organization.
A remaining issue is the extent to which leakiness is
caused by inflammation, perhaps by leukocyte-induced
collateral damage to the endothelium, versus the extent of
leakiness caused by inflammation-independent effects on
endothelial cells. The contributions of these mechanisms
may indeed change over time.
Additional files
Additional file 1: Supplemental Methods.
Additional file 2: Table S1. Effect of minocycline (Mino) treatment on
neuroinflammatory gene and astrogliosis-related gene expression. Mino was
delivered as twice-daily intraperitoneal (ip) injections, with two initial
dosages of 45 mg/kg prior to ischemia and dosages of 22.5 mg/kg just prior
to ischemia and every 12 h for the next 2 d during the reperfusion period
as described in Materials and Methods. One eye of each rat was subjected
to retinal ischemia (IR) for 45 min or needle puncture only (Sham) and after
48 h of reperfusion total RNA was isolated from retinas and relative mRNA
levels of 25 genes shown was assayed by duplex qRT-PCR with β-actin
mRNA serving as an internal control. Gene symbols, Applied Biosystems
(ABI) assay numbers and calculated efficiency of primers obtained in duplex
assays with β-actin primer/probes (or for β-actin primer alone) are shown.
Mean mRNA levels are all relative to that of the no-treatment (NT) Sham
group. Results for IR experiments are the means and standard error of
means obtained from eight animals per group. Percent inhibitions by Mino
are calculated from effects of IR observed in Mino-treated and non-treated
rats ((1 – (Mino-IR – Mino-Sham)/(NT-IR – NT-Sham)) × 100%). For comparison,
× the mean induction of expression mRNAs in retinas (n = 3) at 4 h following
intravitreal injection of 1 μg/eye of lipopolysaccharide (LPS) is shown. P values
for statistical comparisons of means were calculated using Students t-test.
Additional file 3: Figure S1. Intravitreal injection of minocycline (Mino)
inhibited retinal vascular leakage but did not prevent layer thinning or
electroretinogram (ERG) deficits following retinal ischemia (IR). Each animal
in the treatment group was injected with 640 ng of Mino at 4 h prior to IR
and 1 h after reperfusion. Non-treated rats were injected with PBS. One eye
of each animal was subjected to retinal ischemia for 45 min and reperfused
for 24 h. The contralateral eye was subjected to needle puncture only and
served as sham control. A) Twenty-four hours after reperfusion retinas were
assayed for Evans blue dye leakage as described in Materials and Methods.
B) Twenty-four hours after reperfusion retinas were assayed for as DNA
fragmentation described in Materials and Methods. C) Two weeks after
reperfusion, retinal inner plexiform layer (IPL) thicknesses were measured from
cross sections and the ratios of IPL/(OPL +ONL) calculated to represent IPL
thicknesses corrected for non-perpendicular sectioning angles. Results shown
are the means and standard error of means obtained from eight animals per
group. *P ≤0.05, **P ≤0.01 and ***P ≤0.001 by Students t-test. D) One week
after ischemia ERGs were recorded. The b-wave amplitudes for increasing
flash intensities are shown. Using the mixed effects two-way analysis of
variance (ANOVA) model to compare best fits of the data, the effect of IR was
significant (P <0.05) for both Mino and PBS treated eyes, where there was no
significant difference between IR groups of Mino and PBS treated eyes.
Additional file 4: Figure S2. Mino treatment did not inhibit retinal
vascular leakage immediately following retinal ischemia (IR). Mino was
delivered as twice-daily intraperitoneal (ip) injections, with two initial
dosages of 45 mg/kg prior to ischemia and a dosage of 22.5 mg/kg just
prior to ischemia as described in Materials and Methods. Non-treated (NT)
animals received PBS vehicle injections. One eye of each rat was subjected
to retinal ischemia (IR) for 45 min or needle puncture only (Sham) and after
15min of reperfusion retinas were assayed for Evans blue dye leakage (n = 7
to 8 retinas per group). Evans blue dye was injected 15 min after IR and
circulated for 2 h prior to flushing and removal of retinas. ns = not significant,
**P ≤0.01 and ***P ≤0.001 by Student’s t-test.
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